JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Disease Modification in Psoriasis Through Early IL-17 Inhibitor Intervention: A Retrospective Cohort Study

  • 0The Department of Dermatology, Xiangya Hospital, Central South University, No.87 Xiangya Road, Changsha, Hunan 410008, China; Hunan Engineering Research Center of Skin Health and Disease, Central South University, Changsha, Hunan 410008, China; Hunan Key Laboratory of Skin Cancer and Psoriasis, Central South University, Changsha, Hunan 410008, China; National Clinical Research Center of Geriatric Disorders, Xiangya Hospital, Changsha, Hunan 410008, China; Furong Laboratory, Changsha, Hunan 410008, China.
Journal of the American Academy of Dermatology +

|

June 14, 2025

Abstract

BACKGROUND

Although IL-17 inhibitors like Secukinumab and Ixekizumab have shown significant efficacy in psoriasis, the impact of early intervention with biologics to modify the disease course and achieve long-term remission remains unclear.

OBJECTIVES

To examine the potential of early intervention with IL-17 inhibitors for disease modification in psoriasis.

METHODS

We conducted a multicenter retrospective cohort study on moderate-to-severe plaque psoriasis patients who received at least 4 weeks of treatment with Secukinumab or Ixekizumab between April 2019 and April 2023, taking the relapse rate one year after cessation of treatment as the primary endpoint.

RESULTS

Among 400 patients who discontinued treatment after achieving PASI90, the median relapse time was 3.29 months(approximately 14 weeks). Of 141 patients who discontinued treatment after achieving PASI90 for over a year, 24 (88.89%) in the ultra-short disease duration(USDD, psoriasis duration ≤ 1 year) group and 33 (82.5%) in the short disease duration(SDD, psoriasis duration ≤ 2 year) group achieved one year of drug-free remission.

LIMITATIONS

The potential impact of early intervention on comorbidity development was not addressed in this study.

CONCLUSION

Early intervention with IL-17 inhibitors leads to faster responses and may promote disease modification in psoriasis.

Related Concept Videos

T Cell Types and Functions 01:24

963

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

iPS Cell Differentiation 01:22

2.7K

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.

iPSCs have been successfully used to treat age-related macular degeneration (AMD), a form of...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents 01:29

145

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

The JAK-STAT Signaling Pathway 01:20

8.7K

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...